Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well that doesn't really matter, it will be the reference price going forward.
Enter Sarissa and Dr Denner stage left!
His cue to move on it?
Yes or No?
JRoon- November was discussed during the earnings call, the company commented on suspension of operations in Germany in the same call, and a few days ago I posted that a source received information that the negotiations from the last phase of talks ended without agreement between the parties. Today is not news to me.
That "new" reference price won't be reached until mid-late November. By that time we should already have pricing in France, & Spain.
New poll:
.@Amarincorp's repeated failures are MAINLY due to❓️
— Raf (@ra_fun) August 19, 2022
Exactly - I actually endorse and respect holding the line here. It will pain dividends later in other countries.
One MITIGATE come out with blockbuster data - the price goes up ??
Here is ANOTHER buying opportunity to get some after hour shares for
under $1.50 (o:
As other posters have mentioned, this is not a shock after the terminated all
of their sub-contracted sales force in Germany after ER.
Would make all longs feel better if this was to clean up lose ends before
a BO
Curious to see where we open Monday morning?
Have a swell weekend kids...
Cheers!
RT
It's going to be about 20-30% less than what Amarin was asking, that's my guess.
The problem with accepting a lower offer is that it will become the "reference price" for the other EU countries, it will be hard to do so if the offer comes too low.
It's not that they aren't willing to pay for it, it's that they are not willing to pay the price Amarin was asking. This is going to arbitration.
They use a "comparator" to assess how much they should pay, this is the reference pricing model that they use.
Heading to arbitration. We should know by late November whether there is a middle ground that can be reached. I believe there will be.
It's not as if we didn't see this coming. Germany just isn't willing to pay for it.
Going to run a Twitter a poll shortly that I would like for everyone to take .. please.
The way KM was talking on the Q2 cc I must say I'm not surprised, he was practically saying they will go to arbitration.
Been away from this board for quite a while since I reached my limit with the calamitous drops in the share price. Now it seems there is some new interest trying to get the price out of the gutter. I know there are two trials, Mitigate and Brave, driving some new interest. Can anyone bring me up to date on expected public read out dates for these? I see a lot of references to these two but no dates so far.
Michael it's never good when a company files an 8K on a friday evening especially being summertime with little volume.
The whole lot needs firing. I hope Denner returns from the beach ASAP!
So happy our CEO is a brilliant sales person !!!! THIS COMPANY THAT SUCKS BIG TIME !!
michael
If this company doesn't find a partner I fear Vazkepa they will not be recognized for the great potential that it has as a life saving drug. $4 million write off, just what they need!!!
Germany on hold.
https://investor.amarincorp.com/node/22181/html
You are correct. It was dismissed without prejudice.
Another day closing above the 50 day MA. Along with multiple catalysts (potentially near and farther away), I’ll take it:
- European sales and reimbursement decisions
- Approval (hopeful) in China
- Late breakers
- Mitigate, Respect read outs
- Denner next steps??
Potential for broader indications (pain management, Alzimers, cancer(s) and while some of these may seem a long shot and can take a long time to develop, I play the ultra long game…
Have a nice weekend all.
North, You are correct. The complaint against Hikma was dismissed without prejudice. The judge is refusing to sever Hikma from Health Net, so we can't appeal the ruling. That last part I don't understand.
Sleven,
I think the case against Hikma has NOT yet been dismissed with prejudice, thus continues to be referenced in title of court papers. Could be wrong on that opinion/thought.
FFS. Speaking of charts in biotech … look at AUPH
At least AMRN is not bleeding cash on hand as bad and appears to have stabilized their script numbers …. With some major catalysts ahead
Kiwi
Another news review of EPA MOA for relieving chronic pain publication
https://newsazi.com/elucidating-the-molecular-targets-of-eicosapentaenoic-acid-a-natural-remedy-for-chronic-pain-study-finds-that-epa-inhibits-an-important-signaling-molecule-thereby-reducing-chronic-pain/
It was originally against Hikma only. Then Health Net was added. Then against Hikma was dismissed.
It is currently only against Health Net but because the original case was against Hikma, that's why you keep seeing it in the title.
Thx for the charts Capt .
Looks as tho scripts numbers are stabilizing at a weekly rate over 65,000 scripts
Kiwi
Rafun....I wonder if you could clue me in on the pacer posts....are they relative to the Healthnet case or Hikama. I had understood that the Hikama case was done.....yet there seems to be continual references to it in these pacer posts.
Bhatt's comment supports my theory that the efficacy of V in any current CV related trial will be amplified because of Covid and Covid vaccinations
r, why a patient seeing doctors has so much free time to post? Did you post in between seeing patients? Lastly, can you show one of your posts this week that's informative and helpful to this message board regarding Amarin?
Good question . I believe its the number of patients admitted BECAUSE of their Covid diagnosis
According to an RN friend ...It's common to see pregnant women in delivery rooms with Covid . They are there because they are giving birth ...not because they have Covid .
Some comments from Dr Bhatt
$AMRN Hello my friends. Today is Friday, 8/19/2022:
REPORT # 31 For Week Ending 8/12/2022
Thanks once again to @rafunrafun for providing the script data.
You can find the weekly Executive Summary Reports for 2022 here.
https://drive.google.com/drive/folders/1m8IHsRtEk7kroVbyNBjNFBnBn9GCyadH?usp=sharing
Summary: Total OMG-3 Market fell by about 3,000 scripts to 168,330. Market share actually increased for the second week in a row from 61.95% WE 8/5/22 to 62.27% WE 8/12/22. (see Chart#7)
You can find today’s Report for Week Ending 8/12/2022 here:
https://drive.google.com/file/d/14VD7q3Z_fgYJLLuue_KusSSDTW4_6-hp/view?usp=sharing
Here’s Chart # 1: Total Market Scripts
Is there a distinction between hospitalized WITH Covid and BECAUSE of Covid? If not - that’s useless.
Let's take small victories where we can. Thanks Raf, as always, for those numbers. I fully expected a big collapse this week after last week's encouraging numbers. In the past, it's seemed like every fairly decent week was followed by a depressing collapse.
Just a few more weeks before sales begin in England and some foreign revenue can finally begin to trickle in to help cover costs over there. Then the status of the U.S. market will matter less.
Zip. Still a lot of Covid out there
Raf, Thanks for the numbers.
Sleven,
It must be hard for the market and doctors/patients to imagine the rest of what I said also.
https://www.tipranks.com/news/axsome-stock-skyrockets-after-major-fda-approval-should-you-buy?utm_source=advfn.com&utm_medium=referral
north, hard to imagine Auvelity, which is an FDC of two generic drugs (dextromethorphan and bupropion), would commend a BO premium.
Thanks Raf. Seems to be stabilizing but to where no one makes money. Can't understand how the Generics are happy splitting up such a small pie.
Scripts for week ending August 12, 2022
Drug Industry TRx: -3.2% w/w; +9.2% y/y
Vascepa
TRx 65,201; -1.2% (-823) w/w; -19.9% y/y
NRx 29,652; -0.3% (-85) w/w; -17.3% y/y
Ref 35,549; -2.0% (-738) w/w; -21.9% y/y
Lovaza (Fake & Brand)
TRx 63,621; -2.3% (-1,526) w/w; +1.8% y/y
NRx 31,328; -2.7% (-872) w/w; +4.2% y/y
Ref 32,282; -2.0% (-654) w/w; -0.5% y/y
Fake Vascepa
TRx 39,508; -2.6% (-1,040) w/w; As % of total V: 37.7%
NRx 19,401; -4.3% (-879) w/w; As % of total V: 39.6%
Ref 20,107; -0.8% (-161) w/w; As % of total V: 36.1%
Fake Vascepa by Manufacturer
Hikma - TRx 13,999; (+507) w/w; Generic share 35.4%; Total V share 13.4%
Reddy - TRx 18,515; (-1,745) w/w; Generic share 46.9%; Total V share 17.7%
Apotex - TRx 6,994; (+198) w/w; Generic share 17.7%; Total V share 6.7%
Vascepa + Fake Vascepa
TRx 104,709; -1.7% (-1,863) w/w; +7.4% y/y
NRx 49,053; -1.9% (-964) w/w; +9.2% y/y
Ref 55,656; -1.6% (-899) w/w; +5.8% y/y
No, but looking for a retrace in price to get back in.
After some disasters these past few months I wanted to book some profits.
$100M College Whiz Who Scored As Bed Bath And Beyond Squeezed Says He 'Wasn't That Aware It Was A Meme'
https://finance.yahoo.com/news/exclusive-100m-college-whiz-scored-192823638.html
Zip. dont think U can make those assumptions re late breaking submittals .
IMHO they will have stat sig results for the Covid portion of MITIGATE ...but may wait on the CV portion to attain statistical significance
This story is a crazy representation of how manipulated our markets are today:
Ryan Cohen Dumps Entire BBBY Stake, Makes $68 Million As Apes Crushed
This has had a ripple effect on all meme stocks which are down sharply.
Followers
|
1109
|
Posters
|
|
Posts (Today)
|
18
|
Posts (Total)
|
429074
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators ziploc_1 zmanindc Number sleven |
AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote
Y! Finance AMRN Landing Page
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |